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Abstract 
The field of particle therapy is quickly growing and yet its more widespread 
adoption is limited by size, cost, and the need for adaptation to more 
conformal treatment techniques. In order to realize the benefits of this 
modality the equipment used to generate and deliver the beam is evolving. 
The accelerator is one of the key components of this equipment, and its future 
will be dictated by its ability to accommodate clinical requirements. This 
lecture is intended to provide an introduction to these requirements and 
identify how synchrotrons are designed to deliver the desired beams, as well 
as what limitations exist, and expectations for the future of synchrotrons. 
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1 Introduction 
This lecture is intended to offer a perspective on the subject of synchrotrons for particle therapy, about 
where the field is now and where it needs to go. These questions are answered by reference to an analysis 
of the requirements of particle therapy. 
We start with our present view of the near future. The following are some of the recent themes 
that have been driving the development of particle therapy. 
– Beam scanning (‘pencil’ or ‘crayon’, PBS). The method of choice for spreading the beam is 
beam scanning: more particularly, using magnetic fields to move the beam across the target, 
thus ‘painting’ the desired area. The size of the ‘brush’ is the beam size, which is strongly related 
to the properties of the largely unperturbed beam emerging from the accelerator (and the 
subsequent focusing systems). The depth of penetration of the beam is primarily determined by 
the beam energy. 
– Image-guided radiation therapy (IGRT). The beam position is determined by the use of imaging 
technology of some sort. For moving targets, the beam properties may require adjustment by 
feedback during the motion. With protons, in particular, it is possible to image anatomy and 
directly determine the effective stopping power along the path to the target. Proton radiography 
and tomography depend upon the ability of the beam to penetrate the patient, and thus require 
an appropriate beam energy. 
– Adaptive radiotherapy. Imaging techniques and treatment planning must evolve to a point 
where a target today that has a different geometry from yesterday (or a minute ago) can be 
effectively treated. The treatment parameters need to be modified almost on-the-fly. This has 
implications not only for beam delivery but also for quality assurance. 
– End of range. Currently, there is some uncertainty in the range of the particles in the patient. 
This uncertainty results from errors in conversion from X-ray-based imaging and from organ 
motion or redistribution. Such range information can potentially be obtained more accurately 
using particle-based imaging or other on-line detection methods, which would then require 
adjustment of the delivered beam energy during delivery. 
– Ions. It has been suggested that the treatment of a single tumour could benefit from the use of 
multiple particles with different values of linear energy transfer, delivered during a single 
irradiation. 
– Effective cost. It is a continuing concern that the capital investment is higher for particle 
facilities than for some other modalities. The basis of that conclusion may be from inappropriate 
comparisons. In any case, the goal must be to achieve a cost balance in terms of capital 
investment, patient throughput, and treatment efficacy and accuracy so as to be competitive with 
other modalities. 
Consideration of the above goals of particle therapy, as well as the specific clinical requirements 
placed on the beam parameters, should be factored into the requirements for the accelerator. 
2 Flow of requirements 
In any discussion of the future of synchrotrons, the above goals should be kept in mind. As part of this, 
one must clearly define the clinical beam requirements and determine which ones are related to the 
accelerator design. For some parameters, the characteristics of the accelerator are critical to the beam 
delivery process, and for other parameters they are almost irrelevant. One must design the accelerator 
to achieve all the desired clinical goals, not (as in the past) take an existing accelerator and figure out 
how to apply it to some clinical goals. 
The key goals of radiotherapy are: 
– to deliver the required dose; 
– to deliver that dose with a prescribed dose distribution; 
– to deliver that dose in the right place. 
The beam delivery system, which is in between the accelerator and the patient, will play a role in 
how the safe delivery of clinical beam parameters are related to the accelerator parameters. As an 
example of this, Table 1 shows a few possible parameters and the flow of values from the clinical values 
to the beam parameters and then to the accelerator parameters that are involved for the case of a beam 
scanning delivery system. 
Table 1: Sample of flow from clinical values to accelerator parameters 
Clinical parameter Sample clinical value Beam parameter Accelerator 
parameter 
Dose rate 1 Gy/L min ~100 × 109 protons/min Beam current 
Range 32 cm (in water) 226.2 MeV protons Beam energy 
Scanned-beam 
penumbra 
80% to 20% fall-off = 3.4 mm 
(in air) 
3 mm sigma (e−1/2 for a 
Gaussian beam) 
Beam size, beam 
emittance 
As implied by Table 1 and the above text, there is a flow from the clinical requirements and safety 
requirements to the accelerator requirements. This is depicted in Fig. 1. Starting from any position in 
the chart other than the top will likely result in compromised treatment parameters. 
 
Fig. 1: Flow of requirements 
3 Beam delivery modalities 
This lecture is not intended to describe the details of beam delivery modalities for therapy; however, to 
obtain some basis for the accelerator requirements, it is useful to understand some aspects of this 
technology. 
3.1 Beam scattering 
A beam-scattering system uses the effects of multiple scattering when a beam passes through a material 
to spread the beam from the unperturbed ‘pencil’ to a beam size consistent with the target size. In a 
double scattering system (a sample of which is shown in Fig. 2), two scatterers with a special profile are 
used to create a spread-out beam with a uniform transverse distribution as shown in Fig. 3 (lower curve). 
The beam is also spread longitudinally, to obtain a Spread Out Bragg Peak (SOBP) by selectively 
degrading the beam energy in the correct proportions to create a flat, spread-out longitudinal distribution 
as shown in Fig. 3 (upper curve). The properties of the input beam must be tailored to these requirements. 
However, in this case, because of scattering effects, practically speaking only the initial beam energy is 
relevant to the beam delivery unless the SOBP requires current modulation to adjust the relative 
amplitudes of the Bragg peak. The tolerance of the beam position is another factor that needs to be 
controlled in this beam delivery scenario. 
3.2 Beam scanning 
A beam-scanning system uses magnetic deflection, as shown in Fig. 4, to move the unperturbed beam 
across the target cross-section, thus spreading out the beam. The unperturbed beam is characterized by 
a Gaussian profile as in Fig. 5(b), the lower curve. The Gaussian profile is integrated as the beam is 
moved across the target. Longitudinally the beam profile is that of a Bragg peak as in Fig. 5(a), the upper 
curve. The energy of the beam is varied, thus adjusting the beam range in such a way as to obtain the 
desired longitudinal dose distribution. 
 
Fig. 2: Components of a scattering nozzle 
 
Fig. 3: Dosimetric quantities for scattered beams: depth dose (top), transverse dose (bottom) 
 
Fig. 4: Components of a scanning nozzle 
 
Fig. 5: Dosimetric quantities for scanned beams: depth dose (top), transverse dose (bottom) 
4 Dose and dose rate 
The correspondence between an accelerator parameter and a clinical parameter is typically not simple; 
however, crude estimates may enable an order-of-magnitude value to be determined and used for 
preliminary accelerator design. 
4.1 Conversion from beam parameters to clinical parameters 
Here is an example of this conversion. We start with the assumption of an accelerator beam of 150 MeV 
protons and a beam current of 1 nA. This beam is assumed to be incident (via a scanning system) directly 
(without modification or loss) on a target. Therefore: 
– power = joules/second = energy × current 
o e.g., 150 MeV × 1 nA = 0.15 W 
– dose = joules/kg ≡ gray (Gy) 
o dose = (power × seconds)/kg 
o e.g., 150 MeV × 1 nA × 60 s = 9 J (for one minute) 
– water: 1 kg/1000 cm3 = 1 kg/L 
– dose = 9 J/1 kg (in a litre) = 9 Gy 
o 150 MeV, 1 nA = 9 Gy in 1 L in 1 minute 
– But not all energy goes into the target (see Bragg peak) ⇒ 3–6 Gy in 1 litre in 1 minute 
– 1 nA in 60 s ⇒ 60 × 10−9 C ⇒ 3.7 × 1011 protons for 3 Gy 
– Therefore, for 1 Gy in 1 litre we need ~120 gigaprotons (1.2 × 1011) 
o 120 Gp/min ⇒ ~0.3 nA (averaged over a minute, but synchrotrons are cyclic…) 
This gives an indication of the number of protons needed to treat a target, depending upon the 
dose (in Gy) that is prescribed. This number of protons must be extracted from an accelerator in the 
desired time interval. This lecture is about synchrotrons, so all examples will be relevant to these 
devices. 
4.2 Applicability to synchrotrons 
A synchrotron is a closed loop of magnetic components in which particles are stored, accelerated, and 
then extracted (details are discussed in other lectures in this course). During the time the particles are 
stored and accelerated, they must all live nicely with each other. However, they are all charged, and thus 
they repel each other. This effect is called the space charge force and is represented in Fig. 6, which 
indicates the strength of the repulsive/defocusing force across the distribution. 
However, as the particles move, they are a medium carrying a current and since parallel currents 
attract, this attractive force partially cancels the repulsive force, by an amount that depends on the 
magnitude of the current. As the particles move faster, the deleterious space charge effects are reduced. 
Thus the worst-case situation occurs during low-energy injection and the number of charged particles 
that can be stored in the ring depends upon the injection energy of the particles. 
Figure 7 shows a graph of the number of protons that can be stored in various medical 
synchrotrons (the limitation arising from the space charge forces only). Note from the above that 
1 Gy/min in a litre ⇒ 120 gigaprotons/min ⇒ <4 Gp/acceleration cycle (assuming a 2 s cycle), where 
4 Gp = 4 × 109 protons. 
Thus a connection between a prescription and an accelerator constraint is obtained. 
 
Fig. 6: Repulsive forces in a charged beam 
 
Fig. 7: Space charge limits in proton storage rings 
4.3 Beam current issues 
The situation may change depending upon the details of the treatment. A few examples follow. 
– The beam-spreading modality plays a significant role. If scattering is used, the beam current 
incident on the beam delivery system may need to be on the order of nanaoamps, whereas for 
scanning, only tenths of a nanoamp may be required. 
– It may be desired to reduce the number of fractions required to deliver the total dose, in which 
case the dose per fraction would be increased, thus increasing the desired dose rate (so that the 
treatment time per fraction does not increase). 
– Considerations of target motion inside the patient may affect the time constraints on the beam 
delivery. 
– The instrumentation and the beam analysis time will affect the dose rate that can be safely 
applied. 
4.4 Tolerances 
Depending upon the situation, clinical tolerances can have an impact on the machine performance. Here 
is one example. Assume that it is desired to deliver 40 gigaprotons to a target (the total dose in a 
particular field). Clinical tolerance dictates a 2% accuracy in the dose delivery, which results in a 
tolerance of 8 × 108 protons. Assume further that this target has transverse dimensions of 10 cm × 10 cm 
and that the beam spot size used is 5 mm (1 sigma). Thus it will take roughly 20 × 20 beam spots to 
cover the target. These 400 beam spots will each have to be delivered with a tolerance of 2 × 106 protons, 
indicating the level of control required for the beam. Note further that if it takes 100 μs to respond when 
measuring and reacting to the beam delivery (it could take longer), this tolerance translates to a 
requirement of not delivering more than 2 × 106 protons in 100 μs, or a maximum current of 3.2 nA. 
4.5 Extraction effects 
Extracting the beam from a synchrotron is a semi-stochastic process. There are a variety of methods of 
extracting the beam. One can imagine a pail of water in which water is stored and in which a spigot is 
inserted into the bottom with a valve to control when, and at what rate, the water is extracted. The water 
would be expected to come out smoothly, but if it were filled with air bubbles, the result would be 
different. Figure 8 shows an example of the time dependence of an uncorrected resonant extraction. One 
class of extraction method is to divide the transverse space inside the synchrotron into a stable and an 
unstable region. This can be done (in a simplified view) by introducing a non-linear magnetic field, 
which is weaker than the focusing forces in the ring below a certain radius, but larger at a higher radius 
(this is a simplified explanation). An example of the kind of time dependence of the extracted beam that 
can be achieved is shown in the curves in Fig. 9. 
 
Fig. 8: Example of uncorrected time dependence of extracted beam 
 
Fig. 9: Left: phase space of beam, with separatrix for chromatic extraction. Right: example of time dependence of 
chromatic extracted beam. 
In Fig. 9, the curve on the left shows the phase space of the beam, with the intersecting parabolas 
representing the phase space boundaries between stable (inside) and unstable (outside) regions. The time 
dependence of the intensity of a beam extracted from a stretcher ring is shown in Fig. 9 on the right; 
here, special optics were used in the ring to couple the transverse dimensions to the energy in order to 
smooth the extraction [1]. Figure 10 shows an example of a scope trace of a beam extracted from a 
synchrotron used for medical treatment which employs a sophisticated feedback extraction correction 
system. Issues related to the time it takes to turn off the beam (e.g., when the desired dose is reached) 
and the range of controllable intensity play a role in determining the appropriateness of an accelerator 
design. 
 
Fig. 10. Example of corrected time dependence of RF-excited extracted beam 
5 Beam size and shape 
It is desired to deliver a dose to the target but to allow all surrounding tissue to remain unharmed. The 
degree of conformity is related to the shape of the beam incident on the target. As noted earlier, the 
beam may have a Gaussian shape, but it may also have other shapes. A Gaussian shape is particularly 
well suited for scanned beams since Gaussians can combine well and produce a uniform or otherwise 
conformal pattern. Figure 11 shows how multiple Gaussians can be combined to form a flat top. The 
right-hand part of the figure shows that as the Gaussians are separated, the combined dose eventually 
shows the beam structure. 
 
Fig. 11: Left: multiple Gaussians spaced such that resultant summed intensity is uniform. Right: multiple 
Gaussians spaced further apart than optimal, showing the summed intensity structure. 
5.1 Penumbra 
Note that the dose ‘falls off’ at the sides. The steepest fall-off is at the edge of the Gaussian (without 
external collimators). The steepness of this fall-off determines how much dose will be deposited into 
healthy tissue, as shown in Fig. 12. The fall-off region is generally called the penumbra, after the use of 
this term in scattered-beam physics. If it is desired to ensure that the target dose is within 2.5% of the 
nominal dose, then the edge of the target must be contained in the top left part of the distribution in the 
figure (upper box). Suppose, for example, that an important structure occurs in the lower box, to the 
right; assume, for example, that its edge is 5 mm from the edge of the target. Suppose also that the 
physician has determined that this critical structure cannot receive more than 50% of the target dose. 
Using the equation of a Gaussian, 
 
2 2/2e x σ− ,  
one can calculate that the Gaussian shape cannot have an r.m.s. width (one sigma, σ) larger than 7 mm. 
 
Fig. 12. Example of relative intensities of a Gaussian for a given spacing 
If the shape of the beam is not Gaussian, much of the above discussion becomes invalid and 
specific calculations are required to determine the adequacy of the beam for treatment. Note that in some 
synchrotron extraction schemes the beam has a sharp edge in the plane of the extraction (this may occur 
if there is a septum in the synchrotron). 
5.2 Effects of emittance 
The beam size requirements identified above, coupled with the method by which the beam is delivered 
(e.g., whether or not it is delivered through a beamline), can place a constraint on the beam emittance. 
Assuming that it is desired to have a specific beam size at the target and that the final magnetic element 
is at a fixed distance from the target, a larger-emittance beam will have to be much larger than a smaller-
emittance beam at the location of that last magnetic element. If the last magnetic element is on a gantry, 
then the size and weight of the gantry will be affected by this beam size constraint. Figure 13 shows the 
power and weight requirements for a gantry dipole located 3 m away from the patient isocentre as a 
function of the beam size desired. The upper curve is for a beam with an emittance of 25 mm mrad and 
the lower curve is for a beam with one of 5 mm mrad. Thus one can appreciate the ramifications of 
larger- versus smaller-emittance beams (independently of how they are achieved). 
 
Fig. 13: Power and weight of a gantry dipole for a larger-emittance (upper curve) and smaller-emittance (lower 
curve) beam as a function of the desired beam size at the target. 
6 Timing 
There is a possibility of a strong interaction between the time distribution of the beam extracted from 
the accelerator and the beam delivery method. In the past few years, beam delivery for particle therapy 
has evolved into beam scanning as this enables the most conformal dose distribution possible. Therefore 
we will focus on this aspect of beam timing. 
6.1 Beam delivery and accelerator timing 
There are essentially two styles of scanning beam delivery, one that may be called ‘dose driven’ and 
another that may be called ‘time driven’. The first integrates the dose at a given location before moving 
on to the next location. The second assumes that the beam current has the desired stability and uses time 
as the variable to identify the dose deposited at a given location. If, for example, one moves the beam 
continuously, the amount of dose deposited along the beam path in any given time interval is determined 
by the beam current, the scanning speed, or both. If these are not precisely correct, the dose deposited 
will not be precisely correct. Alternatively, one can deposit a dose at a specific location (spot) and wait 
until the dose desired there has been delivered (dose-driven method) before moving onto the next 
location, and therefore the time dependence of the beam (during the time in which the dose is being 
delivered) is not as relevant, with the following exceptions. 
In dose-driven beam delivery, one must stop the beam when the desired dose has been reached. 
There is, however, a time required for the beam instrumentation to measure and analyse this dose, and 
a time required for the beam to be turned off. Thus there is a time lag between the time the system 
decides to turn off the beam and the time the beam is actually turned off. Therefore, either one can 
anticipate that the beam to be delivered in this time frame will be known and begin the turn-off process 
earlier, or one can lower the beam current to ensure that the dose that will be delivered in this time frame 
will not be significant. In addition, in both time-driven and dose-driven continuous scanning, the beam 
turn-off time will occur while the beam is moving, and one must account for the locations that receive 
a dose during the turn-off time. 
The above considerations highlight the importance of knowing the beam extraction stability and 
the turn-off time, as discussed above in Section 4.4. The smoothness and controllability of the extracted 
beam can determine which method of beam scanning can be applied. The smoothness can also determine 
the anticipated time required to turn off the beam. If the extracted beam current is unstable, one must 
prepare for the highest beam current and the dose rate must be reduced. 
6.2 Organ motion 
In some cases, the target moves. One hopes to reduce the dose delivered to healthy tissue, and this poses 
some challenges when the beam delivery has to be done in a time-dependent way. If one could deliver 
the dose simultaneously to the entire 3D volume of the target (as is almost the case with scattered-beam 
delivery), one would only need to consider the location of the moving target as a function of time. One 
could, for example, deliver dose to the entire volume within which the target was moving; then healthy 
tissue would be irradiated, but the target would receive the desired dose in the shortest possible time. If 
the beam is gated on only when the target is in the beam path, then the macroscopic timing capability 
of the accelerator and the time frame of the motion have to be taken into consideration in determining 
the length of the treatment. Figure 14 shows an example of this situation, which depends upon the time 
cycle of the accelerator [2]. A large improvement in the efficiency of a synchrotron for beam treatment 
was achieved with the development of a variable-cycle synchrotron whose injection and extraction can 
be synchronized with the target motion.  
 
Fig. 14: Time dependence of synchrotron operation 
An additional effect arises when the beam delivery is done using scanning, which has a 3D 
position–time dependence. One must consider the timing of the beam delivery, the timing of the target 
motion, and the timing of the accelerator in order to achieve an appropriate dose distribution in a 
reasonable time frame. 
Some types of beam cycle for synchrotrons include rapid cycling with fast, one-turn extraction or 
very short pulses of a periodic (e.g., 30 Hz) beam, where each pulse can be at a different energy. 
Alternatively, one can use slow extraction, pulling out particles from the accelerator as needed, at the 
beam current needed until they are used up. If there are, for example, 1010 particles in the synchrotron, 
then it may take 1 s to use up those particles at the maximum current identified earlier. If more are 
needed, one has to wait for the time it takes to inject and accelerate another bunch. Also, if a different 
energy is needed, one must wait for another acceleration cycle, unless one is able to extract at different 
energy levels during one extraction cycle as shown in Fig. 15 [3]. Note that a breathing cycle can take 
about 3 s.  
 
Fig. 15: Time dependence of beam energy during extraction in a multienergy extraction process 
7 Cost 
If particle therapy is to become more widely used, the cost of particle therapy systems needs to be 
reduced. One must reduce both the building and the equipment costs associated with a facility. Today a 
variety of synchrotrons are being used in medical treatment, some of which are shown in Fig. 16. 
Smaller synchrotrons for ions heavier than protons, using superconducting magnets, are being 
investigated. Proton synchrotrons have already been reduced in size by ProTom and Hitachi (to name 
two), with diameters on the order of 5 m. Some groups are also attempting to reduce the size and cost 
of gantry structures. One facility for proton therapy is already being constructed in an existing 
conventional radiotherapy clinic at Massachusetts General Hospital, with no new building being built 
for the machine (Fig. 17). 
Synchrotrons for heavier ions (e.g., carbon) are much larger, and today resemble a particle physics 
laboratory accelerator; however, smaller systems utilizing superconducting technologies are under 
investigation. 
 
Fig. 16: Some particle therapy synchrotrons currently in operation 
 
Fig. 17: Plan of radiation oncology floor at Massachusetts General Hospital, showing a proton therapy room 
integrated with linacs (space shaded grey). 
8 The future of synchrotrons 
Many developments of the synchrotron have been necessary in order to develop it into an efficient 
accelerator for application in medical particle therapy. The design of the synchrotron must correspond 
to the important treatment parameters. Development work is continuing with the aim of obtaining 
adequate intensity storage while attempting to minimize the cost of higher-energy injection and 
smoothly controllable extraction, with a flexible accelerator cycle that can change the beam energy 
extracted during a single cycle. Thus far, however, all of these capabilities have not been used in any 
one synchrotron for treatment. For proton synchrotrons, the performance has to continue to improve and 
the cost has to continue to decrease. There will be increasing demands for faster treatment without 
compromising accuracy. For heavier particles, the use of superconducting technology can reduce the 
size, but the cost and the rapidity of change of the magnet excitation will be affected. 
There are a number of factors for future consideration (some of which may compete): 
– cost: 
o size vs. superconductivity; 
o injector energy; 
– intensity: 
o injector energy vs. cost; 
– energy: 
o therapeutic energy vs. imaging vs. low (shallow-range) energies; 
– energy change speed: 
o effects of superconductivity; 
o beam storage stability; 
– turn-off time: 
o instrumentation time; 
o analysis time; 
o extraction control; 
– irradiation time: 
o full-volume irradiation in a short time. 
The future development of synchrotrons must be directed towards meeting the demands of 
optimal, safe delivery of particle therapy at a cost that is competitive with conventional radiotherapy 
systems. It is no longer adequate to identify an accelerator and then ask how it can be used for particle 
therapy; this has been done. One now has to optimize the delivery of particle therapy, including the 
beam parameters, timing, size, and cost. Thus far, there is no single standout technology that can 
accomplish all this, but the technology to achieve operation with the desired parameters does exist and 
the field is ripe for new insights and developments. 
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